General description
SB 239063 helps to decrease neutrophilia, inflammatory cytokines, matrix metallopeptidase 9 (MMP-9) and fibrosis in the lung.
Application
SB 239063 has been used to determine the roles of c-Jun N-terminal kinase (JNK), p38 MAP kinase, and extracellular signal regulated protein kinase (ERK)/p42/p44 mitogen activated protein kinase (MAPK) on the viability and apoptosis of cardiomyocytes under glutathione S-transferase (GST) inhibition. It has also been used in neuron-microglia conditioned media (CM) experiments and pharmacokinetics.
Biochem/physiol Actions
Potent p38 MAP kinase inhibitor. Selective for α and β. No activity against γ and δ isoforms.
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Sold for research purposes under agreement from GlaxoSmithKline
- UPC:
- 10161807
- Condition:
- New
- HazmatClass:
- No
- MPN:
- S0569-25MG
- CAS:
- 193551-21-2
akash.verma@cenmed.com
(732) 447-1115





